RenovoRx, Inc., a clinical-stage biopharmaceutical company developing targeted combination therapies, and Imugene Ltd., a clinical-stage immuno-oncology company, entered into a strategic research collaboration to optimize the delivery of Imugene’s oncolytic virus therapy with RenovoRx’s TAMP (Trans-Arterial Micro-Perfusion) therapy platform for the treatment of difficult-to-access tumors.

Imugene and RenovoRx will investigate the ability to administer Imugene’s CF33 oncolytic virus technology with RenovoRx’s TAMP therapy platform. The ability to treat difficult-to-access tumors, such as pancreatic and liver cancers, by delivering CF33 trans-arterially may be valuable to cancer patients compared to traditional administration methods where dense fibrous tissue and lack of blood vessels supplying the tumors have been shown to limit therapy uptake.

In previous studies, the platform demonstrated a 100-fold increase in local tissue concentration with TAMP compared to conventional IV delivery as well as advantages compared to off-the-shelf intra-arterial (IA) delivery. TAMP’s unique approach to treatment delivery offers the potential to increase an oncology therapy’s efficacy, improve safety, and widen its therapeutic window by focusing its distribution uniformly in target tissue.

“We believe the synergy between RenovoRx’s trans-arterial drug delivery system and our CF33 oncolytic virus platform has the potential to facilitate treatment of difficult-to-access cancers and help patients,” said Leslie Chong, Managing Director & CEO of Imugene.

“Our collaboration with Imugene is an important milestone for RenovoRx as we expand our pipeline from exclusively treating locally advanced disease to treating metastatic disease with immunotherapy,” said Shaun Bagai, CEO RenovoRx. “We look forward to combining our proprietary TAMP platform with Imugene’s CF33 oncolytic virus with the goal of optimizing clinical benefits for patients.”